Pomalidomide, bortezomib, and dexamethasone for patients with relapsed or refractory multiple myeloma previously treated with lenalidomide (OPTIMISMM): a randomised, open-label, phase 3 trialPaul G. Richardson, Yen Charles, Jindriska Lindsay et al.|The Lancet Oncology|2019Cited by 383
Belantamab Mafodotin, Bortezomib, and Dexamethasone for Multiple MyelomaVânia Hungria, María-Victoria Mateos, Paweł Robak et al.|New England Journal of Medicine|2024Cited by 162
Results from the randomized phase III DREAMM-7 study of belantamab mafodotin (belamaf) + bortezomib, and dexamethasone (BVd) vs daratumumab, bortezomib, and dexamethasone (DVd) in relapsed/refractory multiple myeloma (RRMM).María‐Victoria Mateos, Vânia Hungria, Paweł Robak et al.|Journal of Clinical Oncology|2024Cited by 21